יחס חוב להיוון בספרים: Theriva Biologics, Inc. (TOVX)

High volatility for Theriva Biologics, Inc. (TOVX) is driven by a lack of sales and uncertainty surrounding clinical trials. The total debt-to-book capitalization ratio confirms these risks, where the 0.27 mark indicates the level of financial conservatism. Theriva Biologics, Inc. (TOVX) relies on FDA approval to bring pancreatic cancer drugs to market, seeking the expansion of VCN-01 oncolytic viruses in the therapy of solid tumors.

Financial autonomy is critical for the biotechnology sector with a focus on clinical trials. This metric compares total liabilities to equity, determining the degree of dependence on borrowed funds. The current debt-to-equity ratio stands at 0.27. For Theriva Biologics, Inc. (TOVX), having excluded mergers, this ratio confirms the stability of its liability structure. A decrease in this indicator guarantees solvency during the period of costly oncology research.